Liquidia (LQDA) CAO Boyle Dana Sells $168K of Stock

Boyle Dana, the Chief Accounting Officer at Liquidia Corporation (LQDA), sold 5,892 shares of the company on October 12, 2026, for approximately $167,804. This sale was part of a planned transaction under Rule 10b5-1.

Other Institutional Activity in Liquidia Corporation

Blackrock Inc. holds 10,788,586 shares of Liquidia, having increased its position by 529,932 shares, valued at about $370.6 million. Farallon Capital Management LLC reduced its holdings by 290,837 shares, bringing its total to 8,365,038 shares worth approximately $287.3 million. Caligan Partners, LP maintained its position with 8,118,892 shares, valued at about $278.9 million. Findell Capital Management LLC also kept its stake intact at 3,502,112 shares, worth around $120.3 million. Vanguard Capital Management LLC increased its holdings by 212,206 shares, totaling 3,139,183 shares valued at about $107.8 million.

Liquidia Corporation Stock Down 2.9%

Recently, Liquidia shares traded around $33.77, which is significantly below its 50-day moving average of $61.62 and its 200-day average of $53.93. The stock is also down about 63.9% from its 52-week high of $93.61, but it remains above its 52-week low of $21.94.

Recent Earnings

For the trailing twelve months, Liquidia reported revenue of approximately $450.9 million, with an earnings per share (EPS) of $1.39. The company has shown remarkable revenue growth of 1,842.7% year-over-year. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Liquidia Corporation

On the same day as Dana Boyle's sale, several other insiders also sold shares. Russell Schundler, General Counsel, sold 13,692 shares for about $389,948. Chief Medical Officer Rajeev Saggar sold 9,218 shares valued at approximately $262,528. Chief Commercial Officer Scott Moomaw sold 8,863 shares for around $252,418, while Chief Human Resource Officer Sarah Krepp sold 5,245 shares for about $149,378. All these transactions were planned sales under Rule 10b5-1.

Analysts Set New Price Targets

On October 1, 2026, Raymond James downgraded Liquidia to an "Outperform" rating with a target price of $53.0, down from $106.0. BTIG also downgraded the stock to "Neutral." Needham maintained its "Buy" rating but lowered its target to $72.0, down from $110.0. Wells Fargo downgraded its rating to "Equal-Weight" with a target of $30.0, down from $108.0. HC Wainwright & Co. kept its "Buy" rating but reduced its target to $58.0 from $130.0. The consensus recommendation for Liquidia is a "Buy," with a mean price target of $54.38 based on eight analyst opinions.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company based in Morrisville, NC. It focuses on developing and commercializing products for rare cardiopulmonary diseases in the U.S. Its lead product, YUTREPIA, is used to treat pulmonary arterial hypertension and related conditions. This insider sale comes amid a backdrop of analyst downgrades and significant insider transactions.

Bottom Line

Investors should watch for Liquidia's next earnings report on November 3, 2026, and keep an eye on further insider transactions and analyst updates as the market continues to react to these developments.